A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 112
- 试验地点
- 16
- 主要终点
- Incidence of lab abnormalities
研究概览
简要总结
This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety and tolerability of ZW49. Eligible patients include those with locally advanced (unresectable) or metastatic HER2-expressing cancers.
详细描述
The study will use a 3+3 dose-escalation study design to evaluate the safety and tolerability of ZW49 and to determine the MTD or RD of ZW49 for further study. Selected expansion cohorts will be subsequently opened based upon Safety Monitoring Committee (SMC) recommendation and sponsor approval to further evaluate the safety and tolerability of ZW49 at the MTD or RD and to assess preliminary anti-tumor activity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically-confirmed diagnosis of breast cancer, gastroesophageal adenocarcinoma (GEA), or other HER2-expressing cancer with evidence of locally advanced (unresectable) and/or metastatic disease.
- •Dose-escalation (Cohort 1): HER2-high advanced solid tumors
- •Expansion (Cohort 2): HER2-high breast cancer
- •Expansion (Cohort 3): HER2-high GEA
- •Expansion (Cohort 4): HER2-high other non-breast and non-GEA cancers
- •Progressive disease that has progressed on or been refractory to all standard of care. Patients who were intolerant to or ineligible for standard therapy may be eligible if the reasons are carefully documented and approval is provided by the sponsor medical monitor
- •Patients with HER2-high breast cancer must have received prior treatment with trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1)
- •Patients with HER2-high GEA must have received prior treatment with trastuzumab
- •Sites of disease assessible per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- •Dose-escalation: measurable or non-measurable disease
- •Expansion: measurable disease
- •ECOG performance status score of 0 or 1
- •Adequate organ function
- •Adequate cardiac left ventricular function, as defined by a LVEF >/= institutional standard of normal
排除标准
- •History of myocardial infarction or unstable angina within 6 months prior to enrollment, troponin levels consistent with myocardial infarction, or clinically significant cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension, or any history of symptomatic congestive heart failure (CHF)
- •Clinically significant infiltrative pulmonary disease not related to lung metastases
- •Active hepatitis B or hepatitis C infection or other known chronic liver disease
- •Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease (with exception of patients with Gilbert's Syndrome, asymptomatic gall stones, liver metastases, or stable chronic liver disease per investigator assessment)
- •Known history of human immunodeficiency virus (HIV) infection
- •Brain metastases: Untreated CNS metastases, symptomatic CNS metastases, or radiation treatment for CNS metastases within 4 weeks of start of study treatment. Stable, treated brain metastases are allowed (defined as patients who are off steroids and anticonvulsants and are stable for at least 1 month at the time of screening).
- •Known leptomeningeal disease (LMD)
研究组 & 干预措施
ZW49
干预措施: ZW49 (Drug)
结局指标
主要结局
Incidence of lab abnormalities
时间窗: Up to 7 months
Number of participants who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including either hematology and chemistry. Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.
Incidence of dose-limiting toxicities (DLTs)
时间窗: Up to 4 weeks
Number of participants who experienced a DLT. DLTs are events that occur following administration of any amount of ZW49 and are considered related to ZW49 per the investigator. DLTs will include only events considered related to ZW49.
Incidence of adverse events
时间窗: Up to 7 months
Number of participants who experienced an adverse event
Incidence of electrocardiogram (ECG) and left ventricular ejection fraction (LVEF) abnormalities
时间窗: Up to 7 months
Number of participants who experienced an abnormal ECG or LVEF
Incidence of dose reductions of ZW49
时间窗: Up to 7 months
Number of doses reduced and number of participants who require a dose reduction
次要结局
- Serum concentrations of ZW49(Up to 7 months)
- Incidence of anti-drug antibodies (ADAs)(Up to 7 months)
- Objective response rate (ORR)(Up to 6 months)
- Disease control rate(Up to 6 months)
- Duration of response(Up to 2 years)
- Progression-free survival(Up to 2 years)